Latest issue of Clinical laboratory
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Why we should be measuring ionized magnesium
, /in Featured Articles /by 3wmediaThe majority of magnesium in the body is located in bone and muscle; however, the small extracellular proportion of ionized magnesium plays an important role in a number of physiologic processes. Generally, when assessing magnesium concentration, total magnesium is measured. This article discusses the importance of ionized magnesium and why we should be directly measuring […]
Tracing footsteps: exploring friendly viruses to diagnose Lyme disease
, /in Featured Articles /by 3wmediaDespite the progress that has been achieved in Lyme disease (LD) diagnostic development in recent years, lack of early and effective diagnosis of LD remains a major cause of misdiagnosis and long-term patient suffering. We invented a novel way of detecting LD-causing bacteria. The new technology could potentially transform LD diagnostics through the innovative use […]
Role of external quality assessment in clinical laboratory quality assurance
, /in Featured Articles /by 3wmediaWhen specimens are analysed in the clinical laboratory, it is crucial that the results that are reported back to the clinician are accurate. If not, at best, results would not be comparable from the same laboratory on different days or between different laboratories at all. At worst, disease could remain undiagnosed or over-diagnosed with the […]
Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes
, /in E-News /by panglobalTakara Bio Europe AB (TBEAB) and PanCryos have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucoseresponsive beta cells and is one of several customers in TBEAB’s new out-licensing programme.
SignalChem enters clinical trial collaboration with Merck to evaluate effect of SLC-391 in combination with pembrolizumab in advanced NSLC
, /in E-News /by panglobalSignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, is collaborating with Merck (MSD) through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).
Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials
, /in E-News /by panglobalPhico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.
ENPICOM and Viroclinics-DDL receive joint MIT Zuid subsidy to accelerate and improve antibody and vaccine discovery and development
, /in E-News /by panglobalViroclinics-DDL, a Contract Research Organization specialized in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have received approval of their joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines ‘wet-lab’ (in vitro) diagnostic and high-throughput sequencing expertise of Viroclinics-DDL and ‘dry-lab’ (in […]
Oxford University and Prenetics collaborate to scale rapid testing tech globally
, /in E-News /by 3wmediaThe University of Oxford, Prenetics Limited, a global leader in diagnostics and genetic testing, and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to further develop the award-winning OxLAMP technology, a rapid, molecular testing technology for infectious diseases.
Celonic Group, University College London in partnership to produce protein therapeutics using CHOvolution platform
, /in E-News /by panglobalCelonic Group, a Swiss-German contract development and manufacturing organization, and University College London (UCL), UK, have set up a partnership to enable UCL to use Celonic’s CHOvolution cell expression platform for the production of therapeutic protein candidates.
Axol Bioscience and Censo Biotechnologies merge to boost iPSC-related technologies
, /in E-News /by 3wmediaAxol Bioscience, a provider of iPSC-derived cells, media, and characterization services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, have merged.